Air Monitoring Legislation May Be Path Forward for Health on Maryland’s Eastern Shore

For years, residents of the Eastern Shore of Maryland have been asking their local legislators and the Maryland Department of the Environment (MDE) to help them with a local problem. They live in communities that are home to industrial-scale poultry operations, where hundreds of thousands of birds are raised in chicken houses next to residential neighborhoods, and they feel that their health is suffering as a result. The stench from the chicken houses is bad enough, they say, but they must also contend with health problems such as asthma and persistent sinus infections, runny noses and headaches that they believe are a result of those poultry operations. Are their health problems caused by the ammonia and other pollutants blown from chicken houses through exhaust fans? There aren’t enough data to answer that question. Read More >

Perdue at USDA Will Threaten Food Safety and Public Health

This blogpost was co-authored by Claire Fitch, Carolyn Hricko, Bob Martin and Jim Yager.

Former Georgia Governor Sonny Perdue finally had his day in front of the Senate, the last in a long line of Trump administration nominees. In the two months since the announcement of his nomination for Secretary of Agriculture, questions have been raised about Perdue’s conflicts of interest, denial of climate change, ethical violations, and efforts to undermine food safety and local control. Read More >

Pfizer will voluntarily suspend sale of roxarsone following results of FDA arsenic study

From Flikr Creative Commons:barryskeates

From Flikr Creative Commons:barryskeates

The FDA announced today that Pfizer Inc., will voluntarily suspend the sale of 3-Nitro (better known as the arsenical drug roxarsone) following the results of an FDA study which found elevated levels of inorganic arsenic in the livers of chicken fed roxarsone compared to a control group. The announcement of both the study results by the FDA and Pfizer’s decision to suspend the sale of roxarsone (beginning in 30 days) come after increasing pressure from both scientific and non-profit sectors calling for the FDA to ban the use of roxarsone and other arsenical-containing drugs used by the animal meat industry. Roxarsone is currently approved for use in swine, turkeys and chickens, , though roxarsone is predominately used by the broiler chicken industry.

According to the FDA press release, the inorganic arsenic levels found in broiler chickens in the study were “very low,” but nevertheless represent an unnecessary risk to public health, as inorganic arsenic is considered a known carcinogen by the FDA. Despite this, FDA representatives today said animals raised using roxarsone are still safe for consumption and there will not be a recall of roxarsone-fed animal meat. “It is curious that the FDA says chickens produced with Roxarsone are safe for consumption, while also acknowledging it poses an increased public health risk,” said Dr. Keeve Nachman of the Center for a Livable Future, who has conducted research on the public health impacts of roxarsone use. “FDA’s study does little to characterize cancer risks to people who have been eating poultry for their entire lives,” he said.

Alpharma, the maker of roxarsone (and a subsidiary company of Pfizer) was alerted by the FDA of their results and voluntarily chose to suspend roxarsone sales for the time being—as roxarsone is found in scores of other veterinary drug formulations, this suspension will impact a variety of drug compounds currently used by the animal meat industry.

As the FDA’s study only tested inorganic arsenic levels in chicken livers, it still remains to be seen if inorganic arsenic is also found in the muscle tissue of animals fed roxarsone—this may be important when the time comes for the FDA to take a formal position on whether or not to enact a complete ban of Roxarsone or other arsenical-based veterinary drugs from use by the animal meat industry.

For now, consumers should consider this removal of roxarsone from animal feed as a major victory for public health—what remains to be seen is whether or not the FDA moves to eventually ban roxarsone and other arsenical-based veterinary drugs from the market and how long Pfizer’s voluntary suspension of roxarsone is maintained.